David H. Raulet is an immunologist who specializes in studying the role of natural killer cells. He is a professor in the Department of Molecular and Cell Biology at the University of California, Berkeley where he also holds the Esther and Wendy Schekman Chair in cancer biology.[1] He was elected to the National Academy of Sciences in 2019.[2] Raulet is also the co-founder of Dragonfly Therapeutics,[3] a company that seeks to use natural killer cells for cancer immunotherapy.

Early life and education

Raulet was born in Buffalo, New York.[2] He graduated from the University of Michigan with a bachelor's degree in microbiology.[4] He then received his Ph.D. in biology from the Massachusetts Institute of Technology.[4] Raulet went on to conduct postdoctoral research in the Department of Pathology at the Perelman School of Medicine at the University of Pennsylvania.[2]

Independent career

Raulet joined the faculty at MIT in 1983, and moved to the Department of Molecular and Cell Biology at the University of California, Berkeley in 1991.[2]

References

  1. ↑ "David H. Raulet | Research UC Berkeley". vcresearch.berkeley.edu. Retrieved 2020-04-01.
  2. 1 2 3 4 "David Raulet". www.nasonline.org. Retrieved 2020-04-01.
  3. ↑ "About". Dragonfly. Retrieved 2021-05-21.
  4. 1 2 "Lab Members | The Raulet Laboratory". mcb.berkeley.edu. Retrieved 2021-05-21.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.